Trachtenberg Aaron J, Manns Braden
Departments of Medicine and Community Health Sciences, Cumming School of Medicine (Trachtenberg); O'Brien Institute of Public Health and Libin Institute for Cardiovascular Health (Trachtenberg, Manns); University of Calgary, Calgary, Alta.
CMAJ. 2017 Jan 23;189(3):E101-E105. doi: 10.1503/cmaj.160650.
The legalization of medical assistance in dying will affect health care spending in Canada. Our aim was to determine the potential costs and savings associated with the implementation of medical assistance in dying.
Using published data from the Netherlands and Belgium, where medically assisted death is legal, we estimated that medical assistance in dying will account for 1%-4% of all deaths; 80% of patients will have cancer; 50% of patients will be aged 60-80 years; 55% will be men; 60% of patients will have their lives shortened by 1 month; and 40% of patients will have their lives shortened by 1 week. We combined current mortality data for the Canadian population with recent end-of-life cost data to calculate a predicted range of savings associated with the implementation of medical assistance in dying. We also estimated the direct costs associated with offering medically assisted death, including physician consultations and drug costs.
Medical assistance in dying could reduce annual health care spending across Canada by between $34.7 million and $138.8 million, exceeding the $1.5-$14.8 million in direct costs associated with its implementation. In sensitivity analyses, we noted that even if the potential savings are overestimated and costs underestimated, the implementation of mdedical assistance in dying will likely remain at least cost neutral.
Providing medical assistance in dying in Canada should not result in any excess financial burden to the health care system, and could result in substantial savings. Additional data on patients who choose medical assistance in dying in Canada should be collected to enable more precise estimates of the impact of medically assisted death on health care spending and to enable further economic evaluation.
医疗协助死亡合法化将影响加拿大的医疗保健支出。我们的目的是确定与实施医疗协助死亡相关的潜在成本和节省情况。
利用荷兰和比利时(医疗协助死亡合法)已发表的数据,我们估计医疗协助死亡将占所有死亡人数的1%-4%;80%的患者患有癌症;50%的患者年龄在60-80岁之间;55%为男性;60%的患者生命缩短1个月;40%的患者生命缩短1周。我们将加拿大人口的当前死亡率数据与近期临终成本数据相结合,以计算与实施医疗协助死亡相关的预计节省范围。我们还估计了提供医疗协助死亡的直接成本,包括医生会诊和药物成本。
医疗协助死亡可使加拿大全国的年度医疗保健支出减少3470万至1.388亿加元,超过实施该措施相关的150万至1480万加元的直接成本。在敏感性分析中,我们注意到,即使潜在节省被高估而成本被低估,实施医疗协助死亡可能仍至少保持成本中性。
在加拿大提供医疗协助死亡不应给医疗保健系统带来任何额外的财务负担,而且可能会带来大量节省。应收集更多关于在加拿大选择医疗协助死亡的患者的数据,以便更精确地估计医疗协助死亡对医疗保健支出的影响,并进行进一步的经济评估。